| The nephrotoxicity of vancomycin EJ Filippone, WK Kraft, JL Farber Clinical Pharmacology & Therapeutics 102 (3), 459-469, 2017 | 356 | 2017 |
| Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire TS Vasu, K Doghramji, R Cavallazzi, R Grewal, A Hirani, B Leiby, ... Archives of Otolaryngology–Head & Neck Surgery 136 (10), 1020-1024, 2010 | 241 | 2010 |
| Acid peptic diseases: pharmacological approach to treatment A Mejia, WK Kraft Expert review of clinical pharmacology 2 (3), 295-314, 2009 | 171 | 2009 |
| Buprenorphine for the treatment of the neonatal abstinence syndrome WK Kraft, SC Adeniyi-Jones, I Chervoneva, JS Greenspan, D Abatemarco, ... New England Journal of Medicine 376 (24), 2341-2348, 2017 | 149 | 2017 |
| Diurnal variation of the human adipose transcriptome and the link to metabolic disease A Loboda, WK Kraft, B Fine, J Joseph, M Nebozhyn, C Zhang, Y He, ... BMC medical genomics 2, 1-16, 2009 | 131 | 2009 |
| Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial WK Kraft, E Gibson, K Dysart, VS Damle, JL LaRusso, JS Greenspan, ... Pediatrics 122 (3), e601-e607, 2008 | 124 | 2008 |
| Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects WK Kraft, PS Chang, MLPS van Iersel, H Waskin, G Krishna, ... Antimicrobial agents and chemotherapy 58 (7), 4020-4025, 2014 | 117 | 2014 |
| Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome WK Kraft, K Dysart, JS Greenspan, E Gibson, K Kaltenbach, ME Ehrlich Addiction 106 (3), 574-580, 2011 | 110 | 2011 |
| Potential for interactions between caspofungin and nelfinavir or rifampin JA Stone, EM Migoya, L Hickey, GA Winchell, PJ Deutsch, K Ghosh, ... Antimicrobial agents and chemotherapy 48 (11), 4306-4314, 2004 | 109 | 2004 |
| Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects RA Blum, A Majumdar, J McCrea, J Busillo, LH Orlowski, D Panebianco, ... Clinical therapeutics 25 (5), 1407-1419, 2003 | 104 | 2003 |
| The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers WK Kraft, B Steiger, D Beussink, JN Quiring, N Fitzgerald, HE Greenberg, ... The Journal of Clinical Pharmacology 44 (1), 67-72, 2004 | 94 | 2004 |
| Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant WK Kraft, MW Stover, JM Davis Seminars in Perinatology 40 (3), 203-212, 2016 | 89 | 2016 |
| Ethanol pharmacokinetics in neonates and infants E Marek, WK Kraft Current Therapeutic Research 76, 90-97, 2014 | 86 | 2014 |
| Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS) AK Mangat, GM Schmölzer, WK Kraft Seminars in Fetal and Neonatal Medicine 24 (2), 133-141, 2019 | 81 | 2019 |
| Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting DH Kim, C Daskalakis, DJ Whellan, IR Whitman, S Hohmann, ... The American journal of cardiology 103 (10), 1391-1395, 2009 | 80 | 2009 |
| Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung … AT Hastie, WK Kraft, KB Nyce, JG Zangrilli, AI Musani, JE Fish, SP Peters American journal of respiratory and critical care medicine 165 (2), 266-272, 2002 | 78 | 2002 |
| Pharmacologic management of the opioid neonatal abstinence syndrome WK Kraft, JN van den Anker Pediatric Clinics 59 (5), 1147-1165, 2012 | 72 | 2012 |
| Prevalence of obstructive lung disease in HIV population: a cross sectional study A Hirani, R Cavallazzi, T Vasu, M Pachinburavan, WK Kraft, B Leiby, ... Respiratory medicine 105 (11), 1655-1661, 2011 | 71 | 2011 |
| Pharmacologic and clinical evaluation of posaconazole JN Moore, JR Healy, WK Kraft Expert review of clinical pharmacology 8 (3), 321-334, 2015 | 67 | 2015 |
| BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study R Nettles, C Chien, E Chung, A Persson, M Gao, M Belema, NA Meanwell, ... Hepatology 48 (suppl 1), 1025A, 2008 | 67 | 2008 |
Scott WaldmanDepartment of Pharmacology & Experimental Therapeutics, Thomas Jefferson UniversityAdresse e-mail validée de jefferson.edu
